| Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI. |
accessnewswire.com |
2025-05-16 18:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm |
LOS ANGELES--(BUSINESS WIRE)--SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm. |
businesswire.com |
2025-05-15 23:07:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-14 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-13 16:31:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or the "Company") (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-12 21:32:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-10 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 |
Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit |
globenewswire.com |
2025-05-08 12:35:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development |
Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care; All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 dose (RP2D) followed by disease specific expansion cohorts Logic-Gated cell therapy approach may have the potential for broad liquid and solid tumor applications, providing multiple pipeline expansion opportunities SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter of 2025 and provided a summary of recent pipeline and corporate highlights. |
globenewswire.com |
2025-05-06 20:35:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or the "Company") (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-06 18:04:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI |
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-05 16:42:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-03 14:00:00 |
Czytaj oryginał (ang.) |
| Shareholder Rights Advocates at Levi & Korsinsky Investigate Senti Biosciences, Inc. (SNTI) Regarding Possible Securities Fraud Violations |
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Senti Biosciences, Inc. ("Senti Biosciences, Inc.") (NASDAQ:SNTI) concerning possible violations of federal securities laws. Senti issued a press release on April 28, 2025, reporting that "enrollment has been stopped" in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd. |
accessnewswire.com |
2025-05-02 14:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-02 14:00:00 |
Czytaj oryginał (ang.) |
| Senti Bio Releases Virtual Investor “What This Means” Segment |
Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 |
globenewswire.com |
2025-05-01 13:15:00 |
Czytaj oryginał (ang.) |
| Senti Biosciences, Inc. Being Investigated on Behalf of Senti Biosciences, Inc. Investors. Contact Levi & Korsinsky For Details. |
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Senti Biosciences, Inc. ("Senti Biosciences, Inc.") (NASDAQ:SNTI) concerning possible violations of federal securities laws. Senti issued a press release on April 28, 2025, reporting that "enrollment has been stopped" in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd. |
accessnewswire.com |
2025-05-01 12:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI |
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Senti Bio Strengthens Leadership Team with Strategic Hires |
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team with the addition of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-02-07 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-02-06 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-02-05 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-02-04 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-02-03 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-31 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-30 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-29 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-28 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-27 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-24 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc |
NEW YORK CITY, NY / ACCESS Newswire / January 23, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-23 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc |
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-22 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-21 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc |
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-20 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-17 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accessnewswire.com |
2025-01-16 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2025-01-15 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2025-01-14 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2025-01-03 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2025-01-02 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Bioscienc |
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-31 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-30 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESSWIRE / December 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-27 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-26 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-23 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosc |
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-20 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Bioscie |
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-19 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc |
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-18 15:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. |
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders. |
accesswire.com |
2024-12-17 15:45:00 |
Czytaj oryginał (ang.) |
| Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics |
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – |
globenewswire.com |
2024-12-16 10:00:00 |
Czytaj oryginał (ang.) |
| Senti Biosciences Announces New Employment Inducement Grants |
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on November 26, 2024, the Compensation Committee of Senti Bio's Board of Directors granted to three new employees stock options to purchase an aggregate of 49,778 shares of the Company's common stock with a per share exercise price of $2.11. These awards were made under the Company's 2022 Inducement Equity Plan (the “Plan”). |
globenewswire.com |
2024-12-03 22:00:00 |
Czytaj oryginał (ang.) |
| SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study |
Senti Bio posts upbeat initial data from a phase I study on SENTI-202 for the treatment of relapsed/refractory hematologic malignancies. Stock soars. |
zacks.com |
2024-12-03 14:00:28 |
Czytaj oryginał (ang.) |
| Why Is Senti Biosciences Stock Surging Over 400% On Monday? |
Senti Biosciences, Inc. SNTI stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. |
benzinga.com |
2024-12-02 13:44:25 |
Czytaj oryginał (ang.) |
| Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing |
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock (the “Preferred Stock”) through a private investment in public equity (the “PIPE”) financing. Senti Bio anticipates the gross proceeds from the PIPE financing to be approximately $37.6 million, before deducting offering expenses. In addition, investors, upon receipt of stockholder approval by the Company's stockholders, will have the right to exercise warrants to purchase up to an additional 25,069,500 in shares of the Company's common stock. The PIPE financing is anticipated to close on or before December 5, 2024, subject to customary closing conditions. The Company has also granted to a certain investor an option to purchase an additional 4,444 shares of Preferred Stock and accompanying warrants for gross proceeds of approximately $10.0 million at a subsequent closing to occur no later than December 27, 2024. |
globenewswire.com |
2024-12-02 09:10:00 |
Czytaj oryginał (ang.) |
| Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML |
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – |
globenewswire.com |
2024-12-02 09:02:00 |
Czytaj oryginał (ang.) |
| Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights |
Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 |
globenewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| Senti Bio to Participate in Upcoming Investor Conferences |
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. |
globenewswire.com |
2024-09-03 12:15:00 |
Czytaj oryginał (ang.) |
| Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights |
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – |
globenewswire.com |
2024-08-13 20:05:00 |
Czytaj oryginał (ang.) |